ZUMA-19 study being conducted as part of a clinical collaboration in the U.S.
Study evaluating the potential effects of lenzilumab (anti-human-GM-CSF monoclonal antibody) prior to Yescarta® (axicabtagene ciloleucel) in adults with relapsed or refractory large B-cell lymphoma

BURLINGAME, CA / ACCESSWIRE / June 30, 2020 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the company's proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that the first patient has been infused in the ZUMA-19 study, which is being conducted in collaboration with Kite, A Gilead Company. Details of the ZUMA-19 study can be found at www.clinicaltrials.gov/ct2/show/NCT04314843.

"We are excited to see this clinical collaboration move forward as we seek to understand the potential benefit of lenzilumab being administered with CAR T therapy in patients with relapsed or refractory large B-cell lymphoma," said Cameron Durrant, MD, chief executive officer of Humanigen.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company's immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for CAR-T to reach its full potential, the Phase III study and the potential future development of lenzilumab in COVID-19or to be approved by FDA for such use or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to our lack of profitability and operate our business as a going concern; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONTACT:

Media

Darcie Robinson
Westwicke, an ICR company
203-919-7905
darcie.robinson@icrinc.com

Investors

Victoria Meissner, MD
Westwicke, an ICR company
646-677-1837
victoria.meissner@westwicke.com

SOURCE: Humanigen, Inc.

ReleaseID: 595635

By combining mainstream credit and debit products with one of Bitcoin's newest developments, lastbit will enable instant cryptocurrency payments through an intuitive mobile app

BERKELEY, CA / ACCESSWIRE / June 30, 2020 / Bitcoin has been around for more than a decade now, but it has yet to deliver on its promise of becoming the new standard for financial systems. As the COVID-19 crisis increases the need to accelerate the digital economy and global financial systems struggle to keep up, the new normal could soon arrive.

With that in mind, lastbit is launching a beta app that aims to make Bitcoin mainstream. The app integrates commonly-used products–such as credit and debit cards–with a Bitcoin and Lightning wallet. In the app, users will interact with products they are familiar with while having access to all of Bitcoin's benefits. When lastbit's app goes live, the option to buy from your favorite shop, pay for coffee and receive rewards, all in Bitcoin, will become a reality.

Building on Top of What Others Have Accomplished

Currently, most Bitcoin companies focus on enabling the cryptocurrency's use case as an investment asset. Through easy-to-use exchanges, trading platforms, and crypto wallets, these businesses provide users simple ways to buy, sell, trade, and store Bitcoin. While these solutions help to increase adoption, they are not enough to take Bitcoin mainstream.

"We believe in the use of Bitcoin as a medium of exchange," said Prashanth Balasubramanian, CEO, lastbit. "One of our goals is to become a catalyst in helping Bitcoin become a payment instrument linked to real economic value. We are thrilled to be working with the latest Bitcoin developments, such as the Lightning Network, to enable use cases that were previously impossible. We work closely with innovative fintechs who develop solutions for fiat currencies to help make Bitcoin as widely accepted and intuitive to use as a credit card."

Solving Some of the Most Critical Issues of Bitcoin

Lastbit's solution looks to solve three critical problems that prevent Bitcoin's mass adoption: price volatility, slow transaction processing, and big barriers to entry for inexperienced users due to the complexity of the technology.

"By tackling these problems, lastbit will not only unlock Bitcoin's real potential for experienced users but will also enable the growth of the cryptocurrency ecosystem for inexperienced users, allowing others in the space to build better products," Balasubramanian said.

Price volatility with Bitcoin can be largely attributed to the inability to use Bitcoin for things other than saving or trading. Even when customers want to spend Bitcoin, most merchants don't accept it as they do not want to deal with its volatility and complexity. As an example, according to coinmap.org, only 19,408 merchants accept Bitcoin as a payment instrument as of this June. Visa and Mastercard, on the other hand, have each tens of millions of merchants accepting their branded products.

Lastbit's solution addresses this issue by eliminating the merchants' exposure to Bitcoin while still allowing users to fund their purchases with the cryptocurrency. Thus, de facto users can pay with Bitcoin while merchants receive their local currency. This novel approach simplifies the road to mass adoption by eliminating the overwhelming challenge of building a network of merchants who directly accept Bitcoin.

Bitcoin speed can't compete with that of leading payment networks, and solutions that solve this are not easily accessible to everyone. To illustrate, in one second, Bitcoin can only process seven transactions whereas Visa can process 24,000. The Lightning Network, a nascent peer-to-peer network on top of Bitcoin, solves this problem (estimated to handle at least 1 million transactions per second) and enables instant Bitcoin transactions. Nevertheless, the technology is far from mass adoption due to the sheer complexity behind its usage.

To solve these two issues, the lastbit mobile app features a "ready-to-go" Bitcoin experience where users can immediately use the Lightning Network in a simple manner. In addition, lastbit's solution will allow experienced users to host their own services if desired. By providing an app that is both intuitive and flexible, lastbit will address the needs of both beginners and veterans.

"We believe Bitcoin will become mainstream once it's useful for everyone," added Bernardo Magnani, VP of Product, lastbit. "The core of our value proposition is to deliver products that abstract away all the inherent complexities of the technologies we work with to empower all our clients with the full benefits of Bitcoin. Facilitating access to Bitcoin for all types of users is key to our mission."

To download the beta app (available in iOS and Android) and sign-up to be first in line for the pre-release visit www.lastbit.io.

Images available here: https://drive.google.com/drive/folders/1rk2vVbMwDrj1meinRNXhQlCPgDjHi3zE?usp=sharing

About lastbit

Lastbit develops solutions to enable the mass adoption of Bitcoin. Incorporating the latest technologies, lastbit creates products that are accessible to both experienced and novice users alike. Lastbit is a member of the elite Visa Fast Track program and an alumni of UC Berkeley's prestigious SkyDeck accelerator. The company is backed by Charlie Lee, managing director of The Litecoin Foundation, Fulgur Ventures, and the BinanceX Fellowship. For more information, please visit www.lastbit.io.

Media Contact:
Erica Zeidenberg
erica@hottomato.net
925-518-8159 mobile
925-631-0553 office

SOURCE: lastbit

ReleaseID: 595708

VANCOUVER, BC / ACCESSWIRE / June 30, 2020 / Graphite One Inc. (TSXV:GPH)(OTCQB:GPHOF) ("Graphite One" or the "Company") Graphite One notes recent policy developments in the U.S. Congress and Executive Branch on Critical Minerals, including graphite. On June 24, 2020 the U.S. Senate Committee on Energy & Natural Resources (ENR) held a hearing titled "Impacts of COVID-19 on Critical Minerals Supply Chains." The Senate hearing took place several weeks after two Presidential Executive Orders expanded U.S. federal policy on strategic and critical minerals ranging from a review of federal project permitting to making critical minerals projects eligible for Defense Production Act Title III loan programs.

"The Senate hearing, in addition to the new Presidential Executive Orders, indicate that the COVID-19 pandemic has underscored to the U.S. Government the risks inherent in depending on foreign supply chains," said Anthony Huston, CEO. "There is no reason for the U.S. to be 100% import-dependent for graphite and other critical minerals essential to 21st Century technology requirements. This sharpened focus on U.S. supply chains underscores the importance of our Graphite Creek project and our mine-to-material plan to establish a long term source of natural graphite and advanced materials graphite processing in the United States."

Senate Energy and Natural Resources Committee Chair Lisa Murkowski (R-AK), who presided over last week's hearing, observed in her opening remarks:

"The COVID-19 pandemic has shown how delicate our supply chains are, and that should be a wakeup call for all of us. Our job is not simply to impose a royalty on mineral production on federal lands and then call it a day. It is to rebuild our supply chains, and to recognize that no realistic level of subsidies and incentives can compete with having raw materials available here at home."

Murkowski highlighted her bill, co-sponsored by Senator Joe Manchin (D-WV), the American Minerals Security Act. According to Senator Manchin, "this bill will connect energy-producing communities, including in states like West Virginia and Alaska, to new markets and job opportunities while laying the groundwork for the Department of Energy to advance new and necessary critical emissions-reducing technologies." A separate Senate bill — the ORE Act introduced by Senator Ted Cruz (R-TX) — adds graphite and other electric vehicle ("EV") battery materials to the list of rare earths as critical minerals designated for federal tax and investment incentives, and pilot project grants to encourage domestic development.

Simon Moores of UK-based Benchmark Mineral Intelligence noted that "The tectonic plates of the [lithium-ion battery] industry have shifted. By 2029, demand for nickel will double, cobalt to grow by 3 times, flake graphite and manganese by four times, and lithium by more than six times."

As the United States considers undertaking a major federally-financed infrastructure program, Moores told the Senate Committee:

"…Instead of dams, you need to build battery megafactories in their multiples. Instead of highways, bridges and tunnels, you need to build the supply chains to enable these megafactories to operate securely and consistently. These include the cathode and anode plants AND the lithium, cobalt, graphite, nickel and manganese sources to feed them."

"Those who invest in battery capacity and supply chains today will hold the sway of industrial power for generations to come," Moores concluded.

In his post-testimony podcast interview with Senator Murkowski, Mr. Moores singled out the Graphite One Project as "a significant graphite deposit in Alaska" during a discussion on the need for the U.S. to develop domestic sources of the key EV Battery materials.1

Nedal T. Nassar, chief of the Materials Flow Analysis Section at the National Minerals Information Center, U.S. Geological Survey (USGS), testified on recent a USGS supply risk study "examin[ing] the risk of mineral commodity supply disruptions to the U.S. manufacturing sector by assessing the likelihood of and exposure and vulnerability to foreign supply disruptions." Dr. Nassar told the Committee that of the more than 50 materials studied, graphite is one of 5 identified "as having the greatest supply risk."2

Graphite One expects Coated Spherical Graphite – one of the materials needed for the lithium-ion mega-factories referenced by Mr. Moores – to be the primary product from its proposed Graphite Creek Mine and Advanced Materials Processing Plant.

GRANT OF OPTIONS

The Company announces that the board of directors of the Company has approved an incentive stock option grant to directors, officers and consultants of the Company for the purchase of 575,000 shares of Graphite One in accordance with the Company's shareholder approved stock option plan. The options are exercisable at a price of $0.35 per share, all vesting immediately and expiring on June 26, 2025.

Upon the granting of the options described above, Graphite One will have 4,060,000 options outstanding, which represents approximately 10% of the 40,609,143 common shares of the Company currently outstanding. Graphite One's stock option plan limits the issuance of options to no more than 10% of the outstanding common shares.

POSTPONEMENT OF CERTAIN FILINGS

The Company also announces that owing to the COVID-19 global pandemic, it intends to delay the filing of its statement of executive compensation as otherwise required by subsections 9.3.1(2) and (2.2) of National Instrument 51-102 – Continuous Disclosure Obligations in reliance on British Columbia Instrument 51-516 – Temporary Exemptions from Certain Requirements to File or Send Securityholder Materials of the British Columbia Securities Commission. The Company expects to include its statement of executive compensation in its management information circular in connection with its 2020 annual general meeting to be held later this year.

About Graphite One Inc.

GRAPHITE ONE INC. (GPH: TSX-V; GPHOF: OTCQB) continues to develop its Graphite One Project (the "Project"), whereby the Company could potentially become an American producer of high grade Coated Spherical Graphite ("CSG") that is integrated with a domestic graphite resource. The Project is proposed as a vertically integrated enterprise to mine, process and manufacture high grade CSG primarily for the lithium-ion electric vehicle battery market. As set forth in the Company's Preliminary Economic Assessment, potential graphite mineralization mined from the Company's Graphite Creek Property, is expected to be processed into concentrate at a graphite processing plant. The proposed processing plant would be located on the Graphite Creek Property situated on the Seward Peninsula about 60 kilometers north of Nome, Alaska. CSG and other value-added graphite products, would likely be manufactured from the concentrate at the Company's proposed graphite product manufacturing facility, the location of which is the subject of further study and analysis. The Company intends to make a production decision on the Project once a feasibility study is completed.

ON BEHALF OF THE BOARD OF DIRECTORS

"Anthony Huston" (signed)

For more information on Graphite One Inc. please visit the Company's website, www.GraphiteOneInc.com or contact:

Anthony Huston
CEO, President & Director
Tel: (604) 889-4251
Email: AHuston@GraphiteOneInc.com

Investor Relations Contact
1-604-684-6730
GPH@kincommunications.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This release includes certain statements that may be deemed to be forward-looking statements. All statements in this release, other than statements of historical facts, are forward-looking statements.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as "proposes", "expects", or "is expected", "scheduled", "estimates", "projects", "intends", "assumes", "believes", "indicates" or variations of such words and phrases that state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved".

Forward-looking information in this release includes, but is not limited to, statements regarding the stage and progress of development of the Graphite Creek Project including the ability to actually produce spherical graphite, results from the 2019 field program, ability to meet produce a Prefeasibility Study by the second quarter of 2020, ultimate further and final results of additional test-work, estimated capital and sustaining costs and the availability of equipment, labour and resources required, the anticipated applications of graphite in high-tech, clean tech, energy storage and national security applications and all other anticipated applications, international demand and ability to transport and enter into such markets, are all forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include: (i) volatile stock price, (ii) the results of the product development test work may not be indicative of the advancement of the project as anticipated, or at all, (iii) market prices, (iv) exploitation and exploration successes, (v) continuity of mineralization, (vi) uncertainties related to the ability to obtain necessary permits, licenses and title and delays due to third party opposition, (vii) changes in government policies regarding mining and natural resource exploration and exploitation, (viii) competition faced in securing experienced personnel, access to adequate infrastructure to support mining, processing, development and exploration activities and continued availability of capital and financing, and (ix) general economic, market or business conditions. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this press release, and the Company undertakes no obligation to update publicly or revise any forward-looking information, except as required by applicable securities laws. For more information on the Company, investors should review the Company's continuous disclosure filings that are available at www.sedar.com.

1 https://podcasts.apple.com/us/podcast/murkowskis-message-podcast/id1519302002?i=1000479632258
2 https://doi.org/10.1126/sciadv.aay8647

SOURCE: Graphite One Inc.

ReleaseID: 595680

TORONTO, ON / ACCESSWIRE / June 30, 2020 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers announces that after careful consideration the Company has decided to postpone its management information circular and the Annual General Meeting ("AGM").

In light of the COVID-19 pandemic and the restrictions on public gatherings enacted by both the Federal and Provincial governments in Canada to help protect the health and safety of its shareholders, employees and stakeholders, Theralase has elected to delay holding its 2020 AGM.

The Company will be relying on the relief granted under Ontario Instrument 51-504 – Temporary Exemptions from Certain Requirements to File or Send Securityholder Materials, in connection with delaying the public filing of its executive compensation disclosure past the end of June 2020 filing deadline until the filing of its management information circular in connection with its next annual meeting of shareholders. With this conditional temporary relief, the Company will be given until December 31, 2020, to send to its securityholders, and file, its next annual general meeting information circular containing the executive compensation disclosure.

The Company is still considering an appropriate format for its annual meeting of shareholders. Information about the annual meeting of shareholders will be provided in due course.

About Theralase® Technologies Inc.

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.

Additional information is available at www.theralase.com and www.sedar.com

This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

1.866.THE.LASE (843-5273) x 304
416.699.LASE (5273) x 304

Kristina Hachey, Chief Financial Officer
khachey@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 595630

CHELYABINSK, RUSSIA / ACCESSWIRE / June 30, 2020 / Mechel PAO (MOEX: MTLR; NYSE: MTL), one of the leading Russian mining and metals companies, reports completion of another stage of its production facility's ecological modernization at Chelyabinsk Coke and Chemical Products Plant (Mechel Coke). The plant has revamped its coke battery #8, which will enable it to decrease waste emissions. Investment in the project totaled 218 million rubles.

The coke battery #8's reconstruction which included replacement of two gasholders, is one step in a series of measures outlined in the company's ecological program as set in the agreement signed by Mechel Group with Chelyabinsk Region's government, Russia's Natural Resources Ministry and Federal Supervisory Natural Resources Management Service.

The coke battery's coke gas offtake system was upgraded, with two new gasholders, gas exhaust pipes and a crude coke gas main installed. The battery's upper paving and a loading chute for raw materials were also replaced. New cooling water and pressed air supply lines, steam pipes and other systems were also installed to ensure the coke battery's reliable and ecologically friendly operations.

The plant installed best available technologies – sealing systems for the gas exhaust pipes, smoke-free coal loading. This will increase the facility's leak tightness and reduce emissions of 1-4 hazard category substances (benzopyrene, benzene, phenol, ammonia, coal dust) by four tonnes a year at this facility alone.

"The coke battery's upgrade is an integral part of the national Ecology project, as well as the quadrilateral agreement signed by the state and the plant. Minimizing emissions of cancerogenic agents is a priority for us, as it has a massive impact on the environment and public health. As a result of our plants fulfilling such agreements and making their facilities more ecologically friendly, by 2024 we will reduce our total waste emissions in Chelyabinsk by no less than 20%," Chelyabinsk Region's Ecology Minister Sergei Likhachev commented.

"Mechel continues to consistently fulfill the obligations the Group assumed regarding reduction of waste emissions, with measures set in the complex ecological program implemented as scheduled. Our nearest plans include installing new systems for reducing waste emissions in Mechel-Coke's chemical workshops, and reconstruction of its coke battery #1," Mechel PAO's Director of Production Planning and Technical Development Anton Levada noted.

***

Mechel PAO
Ekaterina Videman
Tel: + 7 495 221 88 88
ekaterina.videman@mechel.com

***

Chelyabinsk Coke and Chemical Products Plant (Mechel Coke) is a by-product coke plant with over 10 shops and departments. Its primary product is metallurgical coke, manufactured in eight coke-oven batteries. Mechel Coke supplies the needs of Mechel enterprises as well as markets its products domestically and internationally.

***

Mechel is an international mining and steel company. Its products are marketed in Europe, Asia, North and South America, Africa. Mechel unites producers of coal, iron ore concentrate, steel, rolled products, ferroalloys, heat and electric power. All of its enterprises work in a single production chain, from raw materials to high value-added products.

***

Some of the information in this press release may contain projections or other forward-looking statements regarding future events or the future financial performance of Mechel, as defined in the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We wish to caution you that these statements are only predictions and that actual events or results may differ materially. We do not intend to update these statements. We refer you to the documents Mechel files from time to time with the U.S. Securities and Exchange Commission, including our Form 20-F. These documents contain and identify important factors, including those contained in the section captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in our Form 20-F, that could cause the actual results to differ materially from those contained in our projections or forward-looking statements, including, among others, the achievement of anticipated levels of profitability, growth, cost and synergy of our recent acquisitions, the impact of competitive pricing, the ability to obtain necessary regulatory approvals and licenses, the impact of developments in the Russian economic, political and legal environment, volatility in stock markets or in the price of our shares or ADRs, financial risk management and the impact of general business and global economic conditions.

SOURCE: PJSC Mechel

ReleaseID: 595735